Similar to PML-RARA, NPM1 mutations, present in founder clones in 40–50% of AML patient with normal karyotype (35) are stable during the course of the disease, therefore representing an ideal leukemia-specific target for MRD assessment (29, 36, 37). This evidence concerns the gene NPM1 and acute myeloid leukemia.